Cognition Therapeutics reports Q1 EPS (14c), consensus (12c)

“During our first quarter of 2025 and in recent weeks, we continued to advance our Alzheimer’s disease and dementia with Lewy bodies programs,” stated Lisa Ricciardi, Cognition’s president and CEO. “A request was made with the U.S. Food and Drug Administration to schedule an end-of-Phase 2)meeting to review the results from the SHINE study in Alzheimer’s disease and discuss plans for a registrational study. In order to request separate EOP2 meetings for each indication, both need to have a unique FDA program number. For that reason, we recently initiated the process of securing a commercial investigational new drug application for zervimesine in DLB. Once that process is complete, we will request an EOP2 for DLB.”